Desvenlafaxine Tablet, Extended Release
Product Images NDC 72603-556

This text contains information about Desvenlafaxine Extended-Release Tablets. Each tablet contains desvenlafaxine succinate and is equivalent to 100 mg of desvenlafaxine. The usual dosage instructions can be found in the package insert. It is advised to swallow the tablets whole and not crush, cut, chew, or dissolve them. The tablets should be stored at 20° to 25°C. The medication guide can be accessed online or by calling a specific number. This product is manufactured in India by Rubicon Research Ltd. and is a product of Northstar Healthcare Holdings Ltd. Keep this medication out of children's reach.*

This text provides information about an extended-release tablet containing desvenlafaxine succinate, with each tablet having 38 mg equivalent to 25 mg of desvenlafaxine. The tablets are not to be crushed or chewed and should be swallowed whole. It also includes storage instructions and mentions details about manufacturing. The medication guide is available for dispensing, and there is contact information provided for any queries or issues.*

This is a product label for Desvenlafaxine extended-release tablets containing 50 mg strength. It is manufactured by Rubicon Research Ltd. in India and distributed by Northstar Rx LLC in Memphis, TN. Each tablet contains desvenlafaxine succinate equivalent to 50 mg of desvenlafaxine. The usual dosage instructions, storage conditions, and a warning not to crush or chew the tablets are provided. The label instructs pharmacists to dispense a Medication Guide to patients and directs them to a website for more information. A contact number for Northstar Rx LLC is also listed.*

Each film-coated, extended-release tablet by Northstar Rx LLC contains desvenlafaxine succinate 76 mg, equivalent to 50 mg of desvenlafaxine. The product is manufactured by Rubicon Research Ltd. in India. The tablets are meant to be swallowed whole and should not be crushed, cut, chewed, or dissolved. Usual dosage information can be found in the package insert. The tablets should be stored between 20°C to 25°C (68°F to 77°F). Pharmacists are advised to dispense the medication guide provided separately to each patient. For more information, visit www.northstarrxlic.com/products or call 1-800-206-7821. It is important to keep this and all drugs out of the reach of children.*

This text shows data related to the change in Cmax values of Ketoconazole due to inhibition by CYP3A4 inhibitors. The values indicate the geometric mean ratio with corresponding confidence intervals for the change in Cmax relative to the reference when using 1.08 (1.00-1.17) and 1.43 (1.38-1.49). This data is likely part of a study or analysis evaluating the impact of CYP3A4 inhibitors on Ketoconazole metabolism.*

This is a diagram showing the estimated proportion of patients with relapse over time. The x-axis represents the time to relapse in days from randomization, while the y-axis shows the estimated proportion of patients with relapse. The graph compares two groups: Desverla 50mg and Placebo. Desverla 50mg is shown to have a lower relapse rate compared to Placebo based on the data presented in the graph.*

Estimated proportion of patients with relapse (%) over time from randomization in a study comparing Desvenlafaxine with Placebo. The graph shows the percentage of patients experiencing relapse at various time points, with a range from 0 to 200 days.*